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Abstract
Background: Disease management programmes (DMPs) are costly and impose additional work load on general
practitioners (GPs). Data on their effectiveness are inconclusive. We therefore conducted a cluster-randomised
controlled trial to evaluate the effectiveness of the Austrian DMP for diabetes mellitus type 2 on HbA1c and quality
of care for adult patients in primary care.
Methods: All GPs of Salzburg-province were invited to participate. After cluster-randomisation by district, all
patients with diabetes type 2 were recruited consecutively from 7-11/2007. The DMP, consisting mainly of
physician and patient education, standardised documentation and agreement on therapeutic goals, was
implemented in the intervention group while the control group received usual care. We aimed to show superiority
of the intervention regarding metabolic control and process quality. The primary outcome measure was a change
in HbA1c after one year. Secondary outcomes were days in the hospital, blood pressure, lipids, body mass index
(BMI), enrolment in patient education and regular guideline-adherent examination. Blinding was not possible.
Results: 92 physicians recruited 1489 patients (649 intervention, 840 control). After 401 ± 47 days, 590 intervention-
patients and 754 controls had complete data. In the intention to treat analysis (ITT) of all 1489 patients, HbA1c
decreased 0.41% in the intervention group and 0.28% in controls. The difference of -0.13% (95% CI -0.24; -0.02) was
significant at p = 0.026. Significance was lost in mixed models adjusted for baseline value and cluster-effects
(adjusted mean difference -0.03 (95% CI -0.15; 0.09, p = 0.607). Of the secondary outcome measures, BMI and
cholesterol were significantly reduced in the intervention group compared to controls in ITT after adjustments
(-0.53 kg/m²; 95% CI -1.03;-0.02; p = 0.014 and -0.10 mmol/l; 95% CI -0.21; -0.003; p = 0.043). Additionally, more
patients received patient education (49.5% vs. 20.1%, p < 0.0001), eye- (71.0% vs. 51.2%, p < 0.0001), foot
examinations (73.8% vs. 45.1%, p < 0.0001), and regular HbA1c checks (44.1% vs. 36.0%, p < 0.01) in the
intervention group.
Conclusion: The Austrian DMP implemented by statutory health insurance improves process quality and enhances
weight reduction, but does not significantly improve metabolic control for patients with type 2 diabetes mellitus.
Whether the small benefit seen in secondary outcome measures leads to better patient outcomes, remains unclear.
Trial Registration: Current Controlled trials Ltd., ISRCTN27414162.
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The prevalence of type 2 diabetes is rising worldwide for
all age groups due to population growth, ageing, urbani-
sation, increasing prevalence of obesity and physical
inactivity [1,2]. In Austria at least 300,000- 315,000
patients have diabetes type 2 (4.2 - 4.6% of the adult
population) [3]. The prevalence of late diabetic compli-
cations corresponds to the European average as depicted
in the CODE-2-study [4]. In Austria, deficits in imple-
mentation of standard care for type 2 diabetes exist, and
there appears to be a strong demand for management
optimisation [5].
The chronic care model (CCM) has been developed to
improve the care for patients with chronic conditions
like diabetes mellitus type 2 [6]. Disease management
programmes (DMPs) consisting of physician training in
guideline-adherent therapy, patient education, patient
and physician reminders and continuous feedback have
been introduced to implement the CCM in practice.
While it has been shown that interventions containing
at least one component of the CCM are effective in
improving care [7], the benefits of DMPs are still dis-
cussed controversially. In Germany, the nation-wide
mandatory implementation of DMPs by statutory public
health insurances may have led to increasing bureau-
cracy rather than to an improvement in care and there-
fore the programmes have been criticised widely [8].
Current evaluation studies in Germany appear to reveal
benefits of the DMP regarding mortality, but are of lim-
ited validity due to selection bias and retrospective
methodology [9]. A former evaluation study in Upper
A u s t r i as h o w e dp o s i t i v er e s u l ts regarding the effective-
ness of disease management. This programme, too, has
not been evaluated in a randomised controlled trial, and
has been restricted to small samples of highly motivated
physicians [10]. Thus, the current evidence base remains
insufficient to support a general implementation of
DMPs. Large programmes of statutory public health
insurances have never been evaluated in randomised
controlled studies. Published data of randomised con-
trolled trials of private health insurers and in commu-
nity health settings show only limited and inconsistent
success regarding surrogate measures. To date, only one
randomised controlled trial investigating the outcome of
a DMP programme has been published [11]. The study
demonstrated improvement in glycemic control but had
no impact on cardiovascular morbidity and mortality
after six years of observation.
In summary, published data on the effectiveness of
DMPs for diabetes mellitus type 2 are inconsistent and
inconclusive. These findings show the necessity of thor-
ough evaluation of newly designed DMPs by a rando-
mised controlled trial before general implementation.
This is especially true for large public programmes that
impose additional work on the surgeries involved and
additional costs to the health care system. These costs
may only be justified, if the effectiveness of the pro-
gramme is proven.
As public health interventions tend to be complex and
context dependent, evaluation of effectiveness must be
sufficiently comprehensive to account for this complex-
ity. Randomised controlled trials have been described as
the best method for appraising a causal relationship
between a complex intervention and clinical outcomes
[12]. In several instances such as the implementation
p r o c e s so fD M P sb yp u b l i ch e a l t hi n s u r a n c e si n
Germany, the chance for a rigorous evaluation was
missed due to prior general implementation, leading to
persistent scepticism regarding the effectiveness of these
programmes.
Nationwide implementation of a DMP for type 2 dia-
betes called “Therapie aktiv” is currently underway in
Austria. We evaluated whether this DMP designed by
the Austrian statutory public health insurance leads to
an improvement of metabolic control (HbA1c) and pro-
cess quality of care in adults with diabetes mellitus type
2 compared to controls. This is the first study to evalu-
ate a DMP implemented by statutory public health
insurance using a randomised controlled design.
Methods
Design
The study was performed as a pragmatic cluster-rando-
mised controlled superiority trial of a complex interven-
tion with an observation time of one year.
Randomization was carried out at the district level of
the Salzburg province which resulted in a 3-level cluster
design in which the surgery was nested within the dis-
trict, and patients were nested within the surgeries. Ran-
domisation at the patient level would have lead to
contamination effects because a single GP could not
treat certain patients according to usual care and others
according to the DMP. Randomisation at the GP level
would have led to contamination effects because of
overlapping patient groups, especially in rural areas.
The study took place in the province of Salzburg with
a total population of about 500,000 where the estimated
prevalence of type 2 diabetes (about 2.5 to 3%) is lower
than the Austrian average [3].
Participants
Participation in the study was offered to all 275 primary
care physicians having a contract with the public health
insurance (252 GPs and 23 internists providing primary
care). We informed all physicians both in writing and by
telephone about the study and its objectives and asked
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or fax. 98 physicians signed up, 88 GPs and 10 internists
involved in primary care.
Participating physicians were encouraged to continu-
ously recruit all patients with diabetes type 2 who
entered the surgery during the recruitment period (from
July 15 to November 30 of 2007). To avoid differential
recruitment, all patients were asked to declare their will-
ingness to participate in the DMP. Control patients
were told that they would enrol in the DMP after one
year. All patients willing to participate were included in
the study after informed consent according to the
Declaration of Helsinki. Exclusion criteria were demen-
tia/psychiatric illness with inability to participate or to
give informed consent. Patients suffering from a disease
with limited life expectancy such as advanced cancer
were not included as these patients were unlikely to par-
ticipate in the DMP after standard implementation.
Intervention
The DMP “Therapie aktiv” intervention included the
following components:
- A mandatory 10-hour face to face training course for
physicians, designed by the Austrian Diabetes Association
(ÖDG), the Austrian Medical College (Ärztekammer), and
the Austrian Society for General Practice (ÖGAM) con-
sisting of an update in diabetes care, current guidelines of
the ÖDG, and practice management training.
- Nine hours of patient-education in 4 modules with a
group size of 3 to 12 patients. Patient education was
organised by the Working Group for Preventive Medi-
cine Salzburg (AVOS) using the „Düsseldorfer Modell”
curriculum [13,14]. Training was conducted by physi-
cians in their surgeries or in out-patient clinics. Prior to
the implementation of the DMP, these patient modules
were offered throughout the province but not used
widely.
- Standardised documentation of physical examination,
laboratory findings, and diabetes complications in a
DMP-form once a year.
- Structured interdisciplinary care according to the
guidelines of the Austrian Diabetes Association (ÖDG)
[15].
- Agreement on therapeutic goals in a shared patient-
physician decision-making process at three-monthly
intervals.
In the control group, physicians performed usual care.
The physicians of the control group were not permitted
to participate in the 10-hour DMP training course. As
patient education for diabetes has been publicly avail-
able, participation was possible for controls on a volun-
tary basis, but patients were not explicitly invited to
participate.
Baseline examination
At inclusion the following measures were examined:
HbA1c, cholesterol, triglycerides, LDL-and HDL-choles-
terol, height and body weight, systolic and diastolic
blood pressure. Laboratory tests were performed in a
central laboratory contracted by public health insurance.
The laboratory-staff were blinded as to whether the
samples came from the intervention group or from con-
trols. Anthropometric measurements were taken by the
participating physician. Blinding of the physicians was
not possible.
Final examination
After one year the baseline examination was repeated. In
an additional case report form, diagnostic measures (i.e.
HbA1c-checks, ophthalmological and foot examinations)
and participation in patient education were recorded.
Objectives of the study
The study focuses on the question whether the Austrian
DMP “Therapie aktiv” designed and implemented by
statutory public health insurance improves metabolic
control (HbA1c) and quality of care for adults with type
2 diabetes managed in primary care compared to a con-
trol group with usual diabetes care. We hypothesised
that the DMP would lead to a significant reduction of
HbA1c and an improvement in guideline adherent care
(process quality).
Outcome measures
The primary endpoint of the trial was determined to be
t h ec h a n g ei nH b A 1 cf r o mb a s e l i n et o1 2m o n t h s( f i n a l
examination). Secondary outcomes included an
improvement in systolic or diastolic blood pressure,
lipids, and body mass index. Furthermore, we analysed
measures of process quality including the frequency of
HbA1c measurements, eye and foot examinations as
well as participation in patient education.
Sample size
Sample size was calculated using the expected change in
HbA1c from baseline to the final examination. Using an
estimate of standard deviation for HbA1c change of 2%,
a total of 504 patients (252 per arm) was required to
detect a difference of HbA1c of 0.5% with a power of
1-b = 80% using a two-sided two-sample T-Test at a
0.05 significance level. The estimated intra-cluster corre-
lation coefficient was 0.05 at the level of the surgery and
negligible at the district level. In order to have adequate
power, the sample size had to be increased to 984
patients (492 per arm). Assuming a drop-out-rate of
20%, the sample size was adjusted to 615 patients per
arm, or a total of 1230 patients.
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To assure concealment of allocation at the physician
level, GPs and internists were not told whether they
would be in the intervention or the control group until
after obtaining their consent to participate. After com-
pletion of physician recruitment, cluster-randomisation
at the level of the districts was performed with compu-
terised sequence generation. To assure even distribution
of the districts regarding population characteristics
(urban, rural, mixed) and size, the districts were rando-
mised as matched pairs. As the only urban region of the
province, the city of Salzburg was divided into two
study districts, and the small mountain-districts (Pinz-
gau and Lungau) were combined into one study district
yielding a total of 6 study districts: two urban districts
(Salzburg city left to the Salzach river, Salzburg city
right to the Salzach river), two rural districts (Pinzgau-
Lungau and Pongau), and two mixed districts (Tennen-
gau and Flachgau). Thus randomisation led to both
intervention and control groups containing one urban,
one rural and one mixed district. Blinding of physicians
or patients was not possible due to the complexity of
the intervention.
Statistical methods
All data were recorded in the surgeries of the participat-
ing physicians and transferred to the Institute of General
Practice, Family Medicine and Preventive Medicine of
the PMU for further processing and evaluation. We ana-
lysed differences between groups using mixed models in
IBM® SPSS® Statistics18.0 to adjust for baseline charac-
teristics and cluster effects. The Fisher’s Exact Test was
used to check for significant differences regarding para-
meters of process quality (i.e. percentage of patients
with guideline adherent care). Within-group-differences
in pre-post-analysis were tested using the T-Test for
paired samples.
Ethical issues and trial registration
This trial has been approved by the ethics committee of
Salzburg, Austria, and has been registered with Current
Controlled Trials Ltd. (ISRCTN27414162) on July 12,
2007.
Further details of the methodology and study protocol
have been published elsewhere [16].
Results
98 of 275 (35.6%) physicians eligible signed up to parti-
cipate. Five physicians of the intervention group and
one physician of the control group dropped out before
recruiting patients. The remaining 92 physicians (43
intervention group, 49 control group) recruited 1494
patients, 654 in the intervention and 840 in the control
group. In the intervention group, five patients were
excluded because they withdrew consent prior to the
documentation of baseline data. 9.1% (n = 59) of the
patients in the intervention group and 10.2% (n = 86) of
the patients in the control group were lost to follow up
and could not be tracked due to moving away or non-
compliance. Details of the flow of clusters, physicians
and patients through the study are shown in figure 1 as
suggested by the consort statement for cluster rando-
mised trials [17].
Because of the significantly higher number of patients
in the control group, an analysis was carried out to
exclude differential recruitment and selection bias.
Based on the larger population size in the control dis-
tricts, more physicians were included in the control
group. The population size per eligible physician was
comparable (5773 persons/physician in the intervention
group and 5670 persons/physician in the control group).
Neither the participation rate of physicians nor the
number of patients recruited per physician differed sig-
nificantly between groups (table 1).
Baseline data are shown in table 2. There were no sig-
nificant differences between the intervention and the
control group except for BMI and cholesterol, with
intervention patients being slightly heavier and having
higher cholesterol levels than controls.
After an average of 401 ± 47 days (range 300-647),
90.9% of the intervention group (590 patients) and
89.8% of the control group (754 patients) had complete
data regarding primary outcome measure. The number
of patients with complete data for secondary outcome
measures varied slightly (see table 3). Because of the
realities of adherence and retention in a programme
such as the DMP, we evaluated our data in an inten-
tion-to-treat (ITT) approach using the last available data
carried forward method. With regards to primary out-
come measure, we found a decrease in the HbA1c of
0.41% (95% CI 0.32; 0.50) in the intervention group and
a decrease of 0.28% (95% CI 0.21; 0.35) in the control
group. The pre-post-comparison was significant at a
level of p < 0.0001 for both groups (table 3). Secondary
outcome measures including triglycerides, BMI, systolic
and diastolic blood pressure also decreased significantly
in the intervention group in pre-post analysis, but not in
the control group (table 3).
Our ITT analysis using unadjusted between-group-
analysis demonstrated significant reduction of HbA1c
(-0.13%; 95% CI -0.24; -0.02) and BMI (-0.27 kg/m²; 95%
CI -0.45; -0.08) (p = 0.026 and 0.004 respectively, table
4). We calculated intra-cluster correlation coefficients
(ICC) for both levels of clustering (table 5) [18-20],
and then used mixed models to adjust for cluster effects
and baseline value. After adjustment, only weight loss
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intervention group than in controls (p = 0.040 and
0.043 respectively, table 5).
The number of days spent in the hospital was slightly
lower in the intervention group (intervention 2.63 days,
control 2.97 days, difference 0.34 days [95% CI -1.29;
0.61]), but the difference was not significant (p = 0.484
using mixed models).
Process quality measures including the percentage of
patients receiving guideline-adherent foot-, eye-, and
HbA1c-examinations show highly significant differences
between the intervention and control group (table 6).
Also, there were significantly more intervention patients
(49.5%, n = 321) who participated in patient education
than controls (20.1%, n = 169, p < 0.0001).
Discussion
This is the first study investigating the effects of a DMP
designed and implemented by statutory public health
insurance in a randomised controlled trial. Our data
Figure 1 Flow of Clusters and Participants.
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the intervention and the control group favouring inter-
vention. The small benefit, however, was lost after
adjustment for baseline characteristics and ICC. Inter-
estingly, ICC at the level of randomisation (districts)
was negligibly small, but cluster effects at the surgery
level were quite important. This finding suggests that
DMP-effects and diabetes care are rather dependent on
the motivation and effort of the participating physician
than on the DMP. Only the positive effects of the DMP
regarding weight reduction and lowering of cholesterol
persisted after adjustment. Although these effects may
very well be of clinical relevance, they are minor and
Table 2 Baseline data
Intervention Control p-value
Number of patients at baseline 649 840
Percentage of women 49.0% 46.9% 0.43
1
Age (years ± SD) 65.4 ± 10.4 65.5 ± 10.4 0.95
2
HbA1c (% ± SD) 7.46 ± 1.53 7.34 ± 1.31 0.10
2
Creatinine (μmol/l ± SD) 84.86 ± 30.94 84.86 ± 34.48 0.92
2
Triglycerides (mmol/l ± SD) 2.14 ± 1.82 2.00 ± 1.73 0.12
2
Cholesterol (mmol/l ± SD) 5.15 ± 1.14 5.02 ± 1.09 0.02
2
HDL (mmol/l ± SD) 1.35 ± 0.39 1.32 ± 0.36 0.60
2
LDL (mmol/l ± SD) 2.87 ± 0.96 2.87 ± 0.91 0.78
2
Systolic blood pressure
(mmHg ± SD)
141 ± 19 139 ± 17 0.12
2
Diastolic blood pressure
(mmHg ± SD)
83 ± 11 82 ± 10 0.41
2
BMI (kg/m² ± SD) 30.4 ± 5.1 29.7 ± 4.9 0.01
2
1 Fisher’s Exact Test.
2 independent T-Test.
Table 3 Changes within groups in primary and secondary outcome measures
0
Reduction of Intervention Control
n
1 mean
2 95% CI p-value
3 n
1 mean 95% CI p-value
3
primary outcome measure
HbA1c (%) 590 0.41 [0.32; 0.50] <0.0001 754 0.28 [0.21; 0.35] <0.0001
secondary outcome measures
Creatinine (μmol/l) 586 -0.88 [-2.65; 0.88] 0.165 739 0.88 [-0.88; 2.65] 0.504
Triglycerides (mmol/l) 585 0.15 [0.02; 0.27] 0.021 736 0.09 [0.00; 0.17] 0.046
Cholesterol (mmol/l) 585 0.06 [-0.01; 0.14] 0.112 736 0.01 [-0.06; 0.07] 0.797
HDL (mmol/l) 585 -0.02 [-0.04; -0.01] 0.011 736 -0.01 [-0.03; 0.01] 0.209
LDL (mmol/l) 585 -0.01 [-0.08; 0.07] 0.864 736 0.04 [-0.02; 0.10] 0.161
RR systolic (mmHg) 561 2.49 [1.03; 3.94] 0.001 691 0.68 [-0.46; 1.83] 0.241
RR diastolic (mmHg) 561 1.16 [0.35; 1.98] 0.005 691 0.61 [-0.08; 1.30] 0.084
BMI 568 0.31 [0.17; 0.44] <0.001 695 0.04 [-0.09; 0.16] 0.540
0 Reduction is shown as positive number.
1 n per protocol.
2 intention to treat.
3 paired T-Test.
Table 4 Differences between groups regarding primary
and secondary outcome measures
mean difference
1 95%-CI p-value
2
Primary outcome measure
HbA1c (%) -0.13 [-0.24; -0.02] 0.026
Secondary outcome measures
Creatinine (μmol/l) 1.77 [-0.88; 4.42] 0.157
Triglycerides (mmol/l) -0.06 [-0.21; 0.09] 0.417
Cholesterol (mmol/l) -0.05 [-0.16; 0.05] 0.291
HDL (mmol/l) 0.01 [-0.01; 0.04] 0.295
LDL (mmol/l) 0.05 [-0.04; 0.14] 0.314
RR systolic (mmHg) -1.80 [-3.65; 0.05] 0.057
RR diastolic (mmHg) -0.55 [-1.62; 0.51] 0.307
BMI -0.27 [-0.45; -0.08] 0.004
1 Mean difference is calculated as control group value - intervention group
value.
2 independent T-Test, unadjusted
Table 1 Numbers of participating physicians and patients
Intervention Control p-value
Medical doctors eligible 125 150
Medical doctors in the study (n) 43 49
Medical doctors in the study (% of
eligible MDs)
34.4 32.7 0.80
1
Patients recruited 649 840
Patients recruited/medical doctor 15.1 17.1 0.45
2
1 Fisher’s Exact Test
2 Mann-Whitney-Test
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effectiveness of DMPs.
Four systematic reviews have been conducted on
DMP’s [21-24]. One showed that overall DMPs have
positive pooled effect sizes regarding improvement in
care [21]. However, effects seem to be largely dependent
on the individual programme and its particular design.
Thus, physician training improved guideline adherence
in only 50% of the studies, improvement of disease con-
trol was reported in only 38%, and patient education
w a se f f e c t i v ei no n l y4 4 %o ft h et r i a l s .T h er e v i e w
included experimental and quasi-experimental studies
characterised by large heterogeneity and lack of quality.
The most recent review presented similar results with
only 24 out of 66 experimental or quasi-experimental
trials on the effectiveness of DMPs showing significant
improvement in patient care [22]. A systematic review
performed specifically on programmes aimed at diabetes
mellitus showed that DMPs may hold the potential to
better long-term outcome due to improvements in gly-
cemic control, i.e. a pooled estimate of HbA1c reduction
by 0.5 percentage points [23]. However, the validity of
this review is limited due to the inclusion of non-rando-
mised studies and a significant heterogeneity amongst
studies. The results of the fourth review are even less
convincing due to the inclusion of all study types and
settings (non-controlled observational studies as well as
studies performed in HMOs [Health Maintenance Orga-
nisations] and Community Clinics) [24]. This review
also reports a median HbA1c-reduction of 0.5 percen-
tage points (range +0.2 to -5.9).
The HbA1c-reduction in pre-post analysis of our
intervention group (-0.41 percentage points) corre-
sponds to the reductions found in these reviews (0.5
percentage points). Our data suggest that the effect
shown in these studies may largely be due to regression
to the mean rather than to the effect of the DMP. Based
on our data, the true effect is negligible if the HbA1c-
decrease in the control group is taken into account and
the result is adjusted for confounders. Thus our results
confirm a known trend that effects from an intervention
are usually overestimated in non-randomised studies.
DMPs can also be regarded as interventions that fit at
least certain aspects of the chronic care model (CCM)
as described by Bodenheimer et. al. [6]. Of the six com-
ponents, the Austrian DMP contains three: the linkage
to community resources (patient education classes),
prioritising chronic care by the health care organisation
(reimbursement of DMP), and self-management support
(patient education and setting treatment goals by the
patient). Delivery system design, decision support and
clinical information systems have not been fully devel-
oped so far. By integrating these three pillars of chronic
care into the DMP, the effectiveness could probably be
strengthened. It has been shown in a meta-analysis that
interventions for chronic diseases with at least one ele-
ment of the CCM had beneficial effects on clinical out-
comes and processes of care [7].
While the randomised design of our study is an impor-
tant strength, some weaknesses must be considered. We
need to take into account that the participation in a
Table 5 ICCs and adjusted differences between groups
ICC
1 district ICC
1 surgery adjusted
2
mean difference 95%-CI p-value
Primary outcome measure
HbA1c (%) -0.002 0.003 -0.03 [-0.15; 0.09] 0.607
Secondary outcome measures
Creatinine (μmol/l) 0.001 -0.001 -0.96 [-4.16; 2.20] 0.545
Triglycerides (mmol/l) -0.002 0.003 -0.10 [-0.24; 0.05] 0.190
Cholesterol (mmol/l) -0.001 0.006 -0.10 [-0.21; -0.003] 0.043
HDL (mmol/l) 0.002 0.048 -0.01 [-0.05; 0.02] 0.438
LDL (mmol/l) 0.007 0.046 -0.02 [-0.10; 0.07] 0.684
RR systolic (mmHg) 0.002 0.054 -0.50 [-2.06; 1.05] 0.524
RR diastolic (mmHg) 0.009 0.045 -0.13 [-1.03; 0.76] 0.770
BMI -0.001 0.020 -0.53 [-1.03; -0.02] 0.040
1 calculated with GEE
2 mixed models adjusted for baseline value and cluster structure
Table 6 Improvement of process quality by the DMP
Proportion of patients with Intervention Control p-value
1
eye examination 71.0% 51.2% <0.0001
foot examination 73.8% 45.1% <0.0001
patient education 49.5% 20.1% <0.0001
regular HbA1c checks 44.1% 36.0% 0.002
1 Fisher’s Exact Test
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and patient compliance [25]. As typical for pragmatic
trials, blinding was not possible and the knowledge of
being in the intervention or control group may have
influenced the result. Nonetheless, the greater improve-
ment in the intervention group regarding weight and
cholesterol levels as well as the larger effects on process
quality demonstrate that it may be worthwhile imple-
menting DMPs and further develop the systematic dis-
ease management approach to improve chronic care,
especially for patients who are motivated to participate in
such programmes.
Even though we tried to achieve a study design free of
bias, some risk of bias remains. First, only one third of
t h ee l i g i b l eS a l z b u r gp r o v i n c e physicians participated in
the study which may favour selection of more motivated
physicians who are early adopters. We could hypothesise
that the effect of the DMP and especially physician edu-
cation might have been larger if all physicians were
included as less motivated physicians may reveal larger
deficits in patient care thus giving a larger potential for
improvement. Alternatively, the DMP would be of even
less effect in a less motivated group of physicians, as
suggested by the cluster effects at the physician-level in
our study.
Second, patient selection may not have been free of
bias as concealment of allocation was done at the phy-
sician level, but not the patient recruitment level. Dif-
ferential patient recruitment was minimised by asking
physicians to recruit consecutively and having control
group patients sign up for DMP-participation after
completion of the RCT. Baseline data similarity
between the intervention and control groups shows
that the recruitment method chosen largely resolved
this problem.
Third, selection bias could have occurred due to phy-
sicians’ selection of patients or due to a volunteer-based
enrolment strategy in contrast to the “opt out” model
used in the U.S. According to Linden et al., external
validity may be compromised if programme participants
do not adequately represent the population from which
they were recruited [26]. Comparing our data with in-
patient and out-patient data [5], we suspect that
preferably “healthy” participants were recruited for our
trial. However, this might also reflect healthier patient
characteristics in primary care settings. No valid data
representing patient characteristics in primary care are
currently available in Austria. Thus, patients with higher
HbA1c values may have been less motivated and less
compliant despite their greater potential for improve-
ment. Because this was a “pragmatic” study, a dispropor-
tionate recruitment of “healthy” patients may reflect real
life, with recalcitrant cases not opting in for such
programmes.
According to the extension of the CONSORT state-
ment for pragmatic trials, special emphasis should be
put on the generalisability (external validity) of the
results [27]: Our trial is characterised by a high level of
internal validity. Regarding external validity, the results
can be transferred to a DMP implemented and carried
out on a voluntary basis, but might not be completely
applicable to mandatory participation of physicians and/
or patients in a DMP. Also, the results of our study may
not easily be transferable to the Austrian population as
a whole. As stated above, diabetes prevalence in Salz-
burg is slightly lower than in the rest of the country,
due to unknown reasons. The effect of the DMP on
population health in our study may therefore be differ-
ent and maybe less than the effect in a population with
higher diabetes prevalence.
We cannot predict the influence of disease manage-
ment on clinical outcomes based on our observation
period of only 12 months. This problem has been
addressed by other researchers when trying to deter-
mine long term benefits of DMPs [28,29]. The com-
paratively small benefit of the DMP on weight
reduction, cholesterol level, and improvement of process
quality is unlikely to result in significant changes of
early clinical endpoints or all-cause mortality after only
three years as has been hypothesised by Miksch et al.
[9]. However, the United Kingdom Prospective Diabetes
Study (UKPDS) demonstrated that even small differ-
ences in HbA1c may translate into benefits regarding
acute and chronic diabetic complications as well as hos-
pital admissions in the long run [30]. Therefore, a suffi-
ciently powered, equally long follow-up-study will be
necessary to confirm these effects for DMPs such as the
Austrian “Therapie aktiv”. The negative six-year-study
from Denmark mentioned above does not have suffi-
cient power to demonstrate any benefits regarding out-
come or mortality [11]. We are planning to follow up
both intervention and control patients enrolled in our
trial for the following years to detect long term effects
of the DMP.
Conclusions
For the first time, the effects of a DMP implemented by
statutory public health insurance have been evaluated in
a randomised controlled trial. The Austrian DMP “Ther-
apie aktiv” leads to significant weight and cholesterol
reduction, and an improvement of process quality, but
does not influence metabolic control as measured by
HbA1c after one year. We conclude from our data that
the effects of DMPs have probably been overestimated
in earlier non-randomised trials, and that effect sizes in
randomised trials may correspond to the strength of the
intervention. The cluster effects at the level of the GP
suggest that diabetes care depends more on the care
Sönnichsen et al. BMC Family Practice 2010, 11:86
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Page 8 of 10offered by a specific GP than on the widespread imple-
mentation of a programme. Long-term studies are
necessary to investigate whether the improvements in
weight and cholesterol reduction as well as process
quality translate into the prevention of diabetic
complications.
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